Our knowledge of genetic mechanisms involved in cancer initiation, promotion, and progression recently bas expanded. In order to benefit from this expansion and to apply genetic discoveries to current protocols for prevention, screening, diagnosis, treatment, prognosis, and monitoring for minimal residual disease, a working knowledge must be developed of the genetic principles, oncogenes, tumor suppressor genes, and genetic models of carcinogenesis. Genetic susceptibility testing for cancer soon will be introduced into oncology practice through established familial risk counseling programs, and the oncologist must be prepared to address the medical, ethical, legal, economic, psychological, and social issues that accompany this testing.
PetersJ.A.Familial cancer risk Part 1: impact on today's oncology practice. J Oncol Manage.1994; 18–30.
3.
BlattR.J.R.What is the human genome project?Genet Res.1992; 6: 5–12.
4.
Understanding our genetic inheritance: the US human genome project.The first five years, FY 1991–1995.Washington, DC: US Department of Health and Human Services and US Department of Energy, DOE/ER-0452P: April 1990.
5.
JungstE.T., WatsonJ.D.Human genome research and the responsible use of new genetic knowledge. Genet Res.1992; 6: 41–43.
6.
WeinbergR.A.The integration of molecular genetics into cancer management. Cancer.1992; 70(Suppl 6): 1653–1658.
7.
BodmerW.F.Cancer genetics and the human genome. Hosp Pract (Off Ed).1991; 26: 101–117.
8.
HodgsonS.V., MaherE.R.A Practical Guide to Human Cancer Genetics.Cambridge, United Kingdom: Cambridge University Press;1993.
9.
CooperG.M.Elements of Human Cancer.Boston, Mass: Jones & Bartlett Publishers.1992.
10.
FearonE.R., VogelsteinB.A genetic model for colorectal tumorigenesis. Cell.1990; 61: 759–767.
11.
KnudsonA.G.Jr.Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A.1971; 68: 820–823.
12.
FriendS.H., BernardsR., RogeljS.A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature.1986; 323: 643–646.
13.
HuangH.J., YeeJ.K., ShewY.Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science.1988; 242: 1563–1566.
14.
SchneiderK.A.Counseling About Cancer: Strategies for Genetic Counselors.Boston, Mass: Dana-Farber Cancer Institute;1994.
15.
LoveS.M., LindseyK.Dr. Susan Love's Breast Book.Reading, Mass: Addison-Wesley;1990.
16.
FishelR., LescoeM.K., RaoM.R.The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell.1993; 75: 1027–1038.
17.
LeachF.S., NicolaidesN.C., PapadopoulosN.Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell.1993; 75: 1215–1225.
18.
BronnerC.E., BakerS.M., MorrisonP.T.Mutation in the DNA mismatch repair gene homologue hMLHI is associated with hereditary non-polyposis colon cancer. Nature.1994; 368: 258–261.
19.
PapadopoulosN., KinzlerK.W., VogelsteinB.Mutation of a mutL homolog in hereditary colon cancer. Science.1994; 263: 1625–1629.
20.
AaltonenL.A., PeltomakiP., LeachF.S.Clues to the pathogenesis of familial colorectal cancer. Science.1993; 260: 812–816.
21.
ShibataD., PeinadoM.A., IonovY.Genomic Instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet.1994; 6: 273–281.
22.
FeinbergA.P.Genomic imprinting and gene activation in cancer. Nat Genet.1993; 4: 110–113.
23.
CorlissJ.Imprinted genes play role, change rules, in cancer. J Natl Cancer Inst.1993; 85: 1272–1274.
24.
ReikW.Cancer genetics: imprinting in leukaemia. Nature.1992; 359: 362–363.
25.
HaasO.A., Argyriou-TiritaA., LionT.Parental origin of chromosome involved in the translocation t(9;22). Nature.1992; 359: 414–416.
26.
KingM.C., RowellS., LoveS.M.Inherited breast and ovarian cancer: what are the risks, what are the choices?JAMA.1993; 269: 1975–1980.
27.
SwiftM., MorrellD., MasseyR.B.Incidence of cancer in 161 families affected by ataxia telangiectasia. N Engl J Med.1991; 325: 1831–1836.
PaikS., HazanR., FisherE.R.Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb B-2 protein over expression in primary breast cancer. J Clin Oncol.1990; 8: 103–112.
30.
SlamonD.J., GodolphinW., JonesL.A.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science.1989; 244: 707–712.
GlebovO.K., McKenzieK.E., WhiteC.A.Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res.1994; 54: 3703–3709.
33.
ThorA.D., MooreDHII, EdgertonS.M.Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst.1992; 84: 845–855.
34.
IsolaJ., VisakorpiT., HolliK.Association of over expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst.1992; 84: 1109–1114.
35.
AllredD.C., ClarkG.M., ElledgeR.Association of p53 protein expression with tumor cell prolifereation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst.1993; 85: 200–206.
36.
ThorA.D., YandellD.W.Prognostic significance of p53 over expression in node-negative breast carcinoma: preliminary studies support cautious optimism. J Natl Cancer Inst.1993; 85: 176–177.
37.
BrachmanD.G., HallahanD.E., BeckettM.A.p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res.1991; 51: 6393–6396.
38.
LoweS.W., RuleyH.E., JacksT.pS3-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell.1993; 74: 957–967.
39.
HolzmayerT.A., HilsenbeckS., Von HoffD.D.Clinical correlates of MDR1 gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst.1992; 84: 1486–1491.
40.
CulverK.W., BlaeseR.M.Gene therapy for cancer. Trend Genet.1994; 10: 174–178.
41.
ParkJ.W., StaggR., LewisG.D.Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Cancer Treat Res.1992; 61: 193–211.
42.
LiF.P., FraumeniJ.F.Jr.Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome?Ann Intern Med.1969; 71: 747–752.
43.
LiF.P., FraumeniJ.F.Jr., MulvihillJ.J.A cancer family syndrome in twenty-four kindreds. Cancer Res.1988; 48: 5358–5362.
44.
MalkinD., LiF.P., StrongL.C.Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science.1990; 250: 1233–1238.
45.
HallJ.M., LeeM.K., NewmanB.Linkage of early-onset familial breast cancer to chromosome 17q21. Science.1990; 250: 1684–1689.
46.
NarodS.A., FeunteunJ., LynchH.T.Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet.1991; 338: 82–83.
47.
EastonD.F., BishopD.T., FordD.Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families: the Breast Cancer Linkage Consortium. Am J Hum Genet.1993; 52: 678–701.
48.
FordD., EastonD.F., BishopD.T.Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet.1994; 343: 692–695.
49.
MikiY., SwensenJ., Shattuck-EidensD.A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science.1994; 266: 66–71.
50.
FutrealP.A., LiuQ., Shattuck-EidensD.BRCA1 mutations in primary breast and ovarian carcinomas. Science.1994; 266: 120–122.
51.
CastillaL.H., CouchF.J., ErdosM.R.Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet.1994; 8: 387–404.
52.
Shattuck-EidensD., McClureM., SimardJ.A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. JAMA.1995; 273: 535–541.
53.
American Society of Human Genetics, 1994 annual meeting, late breaking news plenary section.Am J Hum Genet.1994; 55(SuppI 3): 23.
54.
WoosterR., NeuhausenS.L., MangionJ.Localizaton of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–13. Science.1994; 265: 2088–2090.
55.
KnoppersB.M., ChadwickR.The Human Genome Project: under an international ethical microscope. Science.1994; 265: 2035–2036.
56.
DurfyS.J.Case study: for the benefit of all. Hastings Cent Rep.1993; 23: 29.
57.
LiF.P., GarberJ.E., FriendS.H.Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst.1992; 84: 1156–1160.
58.
BieseckerB.B., BoehnkeM., CalzoneK.Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA.1993; 269: 1970–1974.
59.
National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA.1994; 271: 785.
60.
Statement of the American Society of Human Genetics on genetic testing for breast and ovarian cancer predisposition.Am J Hum Genet.1994; 55: i–iv.
61.
PetersJ.A.Case report: for the benefit of all - commentary. Hastings Cent Rep.1993; 23: 30.
62.
Ad Hoc Committee on Genetic Counseling of the American Society of Human Genetics: Genetic Counseling Definition. Am J Hum Genet.1975; 27: 240–242.
63.
LynchH.T., LynchJ.F.Breast cancer genetics in an oncology clinic: 328 consecutive patients. Cancer Genet Cytogenet.1986; 22: 369–371.
64.
LynchH.T., LynchJ.F.Familial predispostion and cancer management. Contemp Oncol1993: 12–25.
65.
KellyP.T.Understanding Breast Cancer Risk.Philadelphia, Pa: Temple University Press;1991.
66.
KellyP.T.Breast cancer risk analysis: a genetic epidemiology service for families. J Genet Counsel.1992; 1: 155–168.
67.
PetersJ.A.Breast cancer risk counseling. Genet Resource.1994; 8: 20–25.
68.
SchneiderK.A., DillerL.R., GarberJ.E.Overview of familial cancers. Genet Resource.1994; 8: 12–19.
69.
HoskinsK.F., StopferJ.E., CalzoneK.A.Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA.1995; 273: 577–585.
70.
WellischD.K., GritzE.R., SchainW.Psychological functioning of daughters of breast cancer patients, Part II: characterizing the distressed daughter of the breast cancer patient. Psychosomatics.1992; 33: 171–179.
71.
KashK.M., HollandJ.C., HalperM.S.Psychological distress and surveillance behaviors of women with a family history of breast cancer. J Natl Cancer Inst.1992; 84: 24–30.
PetersJ.A.“Psychosocial Concerns for Persons at Risk.” Presentation at NSGC Course on ABCs of Cancer Genetics, 1993; Atlanta, Ga.
74.
OffitK., BrownK.Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol.1994; 12: 1724–1736.
75.
ClausE.B., RischN., ThompsonW.D.Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer.1994; 73: 643–651.
76.
GailM.H., BrintonL.A., ByarD.P.Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst.1989; 81: 1979–1886.
77.
AndersonD.E., BadziochM.D.Risk of familial breast cancer. Cancer.1985; 56: 383–387.
78.
AndersonD.E., BadziochM.D.Combined effect of family history and reproductive factors on breast cancer risk. Cancer.1989; 63: 349–353.
79.
EliasS., AnnasG.J.Generic consent for genetics creening. N Engl J Med.1994; 330: 1611–1613.
80.
LiF.P., MontesanoR.Interactions of cancer susceptibility genes and environmental carcinogens: American Association for Cancer Research (AACR) - International Agency for Research on Cancer (IARC) Joint Conference. Cancer Res.1994; 54: 4243–4247.
